28 Sep
2021

How expedition is changing Australian pharma patent disputes

A trend towards increasing expedition in Australian pharma patent disputes has strategic implications for originators and generics/biosimilars alike, argue David Fixler, Rachelle Downie, Colette Downie and Sarah Catania of Corrs Chambers Westgarth

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth